Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04371445 · ClinicalTrials.gov registry record · Phase 4
Dextenza in the Post-op Management of Vitreoretinal Surgeries
A Phase 4 study of Postoperative Pain and Ocular Inflammation, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04371445: Recruiting Phase 4 study of Postoperative Pain and Ocular Inflammation, sponsored by The Cleveland Clinic.
NCT04371445 is a Phase 4 study of Postoperative Pain and Ocular Inflammation that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 30 participants, below the 232-participant average among 120 other Postoperative Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04371445, a Phase 4 study of Postoperative Pain and Ocular Inflammation, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group. Patients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.
Primary Outcome
Percentage of patients with Inflammation following surgery as assessed from 0-4+ cell and flare based on the Standardization of Uveitis Nomenclature \[SUN\] Working Group grading scheme at day 14
Conditions Studied
Interventions
- DRUG Dexamethasone Ophthalmic Insert
- DRUG Prednisolone Acetate 1% Oph Susp
Study Locations (1)
Ohio
- Cole Eye Institute, Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 4 |
What NCT04371445 shows while recruiting
NCT04371445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 232-participant average among 120 other Postoperative Pain trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Postoperative Pain appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone Ophthalmic Insert is the first listed.
NCT04371445 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04371445 about?
NCT04371445 is a clinical study titled "Dextenza in the Post-op Management of Vitreoretinal Surgeries". This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group. Patients must be 18 years of age and older, of any race and...
What is the current status of trial NCT04371445?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2020-06-01. Estimated completion is 2026-05-01.
What conditions does trial NCT04371445 study?
This clinical trial studies the following conditions: Postoperative Pain, Ocular Inflammation, Post-Operative Inflammation, Vitreoretinal Surgery.
What interventions are being tested in trial NCT04371445?
The interventions under investigation include: Dexamethasone Ophthalmic Insert (DRUG), Prednisolone Acetate 1% Oph Susp (DRUG).
Who is sponsoring clinical trial NCT04371445?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04371445 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04371445's enrollment target sits among peer trials
30 115th of 120 higher than 5 of 120 other Postoperative Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postoperative Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse
RECRUITING · Phase 4
-
QL Block in Laparoscopic Myomectomy
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
-
A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi
RECRUITING · Phase 4
-
Preoperative Acetazolamide
RECRUITING · Phase 4
-
Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI